Articles tagged with Cell Therapies
Three University Hospitals and Case Western Reserve University research teams received $50,000 Collaborative Science Pilot Awards to explore innovative research projects. The awards aim to increase competitiveness and capacity for major external funding opportunities in key areas such as cancer, brain health and genetics.
Researchers are exploring natural killer cells as a potential treatment for neuropathic pain, which is caused by nerve damage. NK cells may help prune damaged nerve cells, providing relief from chronic pain.
Researchers at MD Anderson Cancer Center have engineered a new model of aggressive renal cell carcinoma, highlighting molecular targets and genomic events that trigger chromosomal instability. The loss of interferon receptor genes plays a pivotal role in allowing cancer cells to become tolerant of chromosomal instability.
Cartesian Therapeutics has successfully treated patients with generalized myasthenia gravis using an RNA CAR-T therapy. The trial demonstrated marked and long-lasting clinical improvement, with three patients achieving complete or near-complete eradication of disease symptoms.
Peruvoside has been discovered to prevent up to 12 medically important viruses, including SARS-CoV-2, Hand, Foot and Mouth Disease (HFMD), and Influenza. The compound acts on GBF1 protein, disabling its functionality and stopping virus production.
A small-scale clinical trial suggests a modified CAR-T therapy could effectively reduce myasthenia gravis symptoms, with three patients showing complete elimination of symptoms. The treatment was well-tolerated and has the potential for longer-lasting results compared to current treatments.
Recent studies in the New Journal of Pharmaceutical Analysis feature novel diagnostic tools, RNA sequencing-based workflows, and mechanical property evaluations to enhance cancer and cardiovascular disease treatment outcomes. These innovations aim to improve the therapeutic effect of drugs and promote personalized medicine.
Researchers have identified anti-malarial properties in cancer drugs, offering a potential solution to the growing crisis of drug-resistant malaria. The study found that certain protein kinase inhibitors exhibited strong anti-malarial effects, highlighting a new approach to accelerating drug discovery.
Researchers developed Precious1GPT, a multimodal transformer-based approach for aging clock development and feature importance analysis. The model utilizes methylation and transcriptomic data to predict biological age and identify disease-related genes, providing a pathway for therapeutic drug discovery.
Researchers found a link between short telomeres in ATII cells and lung fibrosis in post-COVID-19 patients. The study revealed loss of ATII cellularity and shorter telomeres concomitant with increased fibrotic lung parenchyma remodeling.
UCF researcher Dr. Justine Tigno-Aranjuez has discovered a new receptor that recognizes house dust mite allergens, opening up potential for broad-spectrum therapy. The finding could lead to improved treatments for common allergies, including asthma.
Researchers at UCL have developed base-edited T-cells that can fight leukemia, showing promise in a NHS clinical trial. Three patients with relapsed T-cell leukaemia were treated with the cells, with one patient experiencing complete remission after just four weeks.
Researchers have identified LP-284 as a novel acylfulvene compound with anti-tumor activity against non-Hodgkin's lymphoma. The compound exerts nanomolar potency in 15 NHL cell lines and prolongs survival of mantle cell lymphoma xenograft mice, making it a potential therapeutic option for patients with HR or TC-NER deficiency.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have developed a new therapy that uses engineered macrophages to eliminate solid tumors. The treatment works by silencing a molecular pathway that prevents white blood cells from attacking cancer cells, allowing them to recognize and destroy tumoroids.
Researchers found that blocking histamine-releasing factor (HRF) and immunoglobulin E (IgE) interactions may provide relief for patients with severe asthma. The study, published in The Journal of Allergy and Clinical Immunology, suggests two potential therapies, including HRF-2CA and a therapeutic antibody called SPF7-1.
A study has identified a potential treatment target for prostate cancer that is resistant to hormone therapy, a protein modification involving TRAF4. The researchers found that TRAF4 promotes the spread of cancer and may be associated with a new treatment option for patients.
Scientists from Institut Pasteur and Inserm discovered that CD4 T cells can remotely neutralize tumor cells by producing interferon gamma, offering new hopes for patients with incomplete responses to CAR T cell therapy. This study raises the possibility of personalized treatment approaches using larger quantities of CD4 CAR T cells.
Indiana University School of Medicine researchers will investigate muscle-directed gene therapies and test alternative treatment options for degenerative disorders like Duchenne muscular dystrophy. The goal is to develop more successful and long-term ways to help patients living with muscle disorders.
Researchers at UCLA have developed a new method to bioprint miniature tumor organoids that can mimic the function and architecture of real tumors. This allows for the accurate measurement of individual organoids, enabling the identification of personalized treatments for people with rare or hard-to-treat cancers.
A study published in JAMA Oncology suggests that stopping immunotherapy after two years for patients with advanced non–small cell lung cancer who remain responsive may be a reasonable strategy, providing sustained clinical benefit. The findings provide reassurance for patients and their healthcare providers.
Researchers developed a method to 'tip the balance' of immune cells from bad to good, reversing MS-like symptoms in 100% of mice and achieving full recovery in 38%. The therapy uses biodegradable microparticles to deliver three key therapeutic agents, including rapamycin and a myelin peptide.
An observational study of 329,000 Medicare admissions found that older persons receiving hospital care from allopathic (M.D.) or osteopathic (D.O.) physicians experience similar quality and cost of care. Researchers also highlight systemic health inequities faced by persons with sickle cell disease.
Researchers discuss chemotherapeutic resistance in recurring ovarian cancer, focusing on the unfolded protein response and its effect on polyploid giant cancer cells. Understanding this mechanism could lead to investigating cancer cell molecular mechanisms and potential therapeutic strategies.
Researchers have discovered that HER3 plays a crucial role in promoting cell survival in metastatic colorectal and pancreatic cancer. The surrounding liver microenvironment activates HER3, making it an emerging therapeutic target for these types of cancer.
Researchers discovered that FDA-approved HDAC-inhibitors can impact energy metabolism in solid tumor cells, including glioblastoma. The combination of HDAC-inhibitors and imipridones may synergize to enhance killing of GBM cells by reversing cellular respiration.
Researchers developed predictive models to design RNA-binding inhibitors for disease treatment by regulating protein production. The study identified three key features for effective oligonucleotides: thermostability, serum resistance, and RNase H sensitivity.
Researchers at UCLA Jonsson Comprehensive Cancer Center have found a potential therapeutic target, IL-21, to reduce endocrine autoimmune side effects from checkpoint immunotherapy. A specific group of immune cells play a central role in this autoimmune attack and blocking IL-21 prevents thyroid autoimmunity.
Researchers used cancer proteomics data to identify gene candidates for therapeutic targeting, focusing on protein kinases in uterine endometrial cancer cells. Public molecular resources and multi-omics data analysis can prioritize genes of interest for future studies.
Scientists have engineered plants to produce peptides with antibiotic activity against drug-resistant pathogens, which also enhances stability and prolongs activity. The resulting plants yield potent drugs at significantly lower costs than traditional methods, making them an environmentally friendly option for pharmaceutical production.
University of Pittsburgh researchers created a universal receptor system allowing T cells to recognize any cell surface target. This enables highly customizable CAR T cell and other immunotherapies for treating cancer and diseases, with potential applications in solid tumors.
A new study led by Mass General Brigham researchers found that 88% of rare disease experts agree on the benefits of genomic sequencing in newborn screening. The experts recommended screening for over 600 genetic conditions, including those associated with hemophilia and retinoblastoma.
Researchers at Mount Sinai have discovered a previously unknown way in which the brain and immune system interact in multiple sclerosis. They found that the inflammatory protein interleukin-3 (IL-3) coordinates this communication, inciting the recruitment of immune cells to the brain and exacerbating brain inflammation.
Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.
Researchers review current treatment updates for systemic light chain (AL) amyloidosis, highlighting the need for early diagnosis and effective maintenance therapy. The article discusses the relationship between AL amyloidosis and monoclonal gammopathy of undetermined significance (MGUS), emphasizing the importance of regular monitoring.
A new study presents a chronic wound murine model that characterizes the role of persistent senescent cell accumulation in delayed wound closure. The molecular profiles of senescent cells demonstrate the adverse influence of SASP factors, highlighting a potential root-cause-driven therapeutic strategy.
Researchers developed a new approach to genetic engineering of cells, promising improvements in speed and efficiency over current methods. The technique uses special cell-penetrating peptides to deliver CRISPR-Cas molecules into cells with up to 100% efficiency and low toxicity.
Researchers have identified ATAD3A as a molecular determinant that favors the development of head and neck cancer. The protein is involved in various cellular processes, including energy metabolism and apoptosis. Targeting ATAD3A could offer a novel approach to developing effective anti-cancer therapeutics.
Rice University scientists developed a screening technique to identify high-performing biomaterials for encapsulating insulin-secreting cells, providing long-term blood sugar level control in diabetic mice. The study's findings have the potential to open the door to a more sustainable and self-regulating way to treat Type 1 diabetes.
Researchers at the University of Colorado Cancer Center have made a breakthrough in treating pancreatic cancer by combining radiation and immunotherapy. The treatment eradicates tumors while stopping the cancer from spreading, offering new hope for patients. Clinical trials are planned to further develop this therapy.
Researchers at Michigan State University have developed a gene therapy that successfully treats a form of progressive retinal atrophy in dogs with an inherited eye disease. The therapy is now being prepared for human clinical trials to treat retinitis pigmentosa, a rare genetic disorder causing vision loss.
A novel cell signaling pathway has been identified that could be targeted to treat aggressive pancreatic cancers. The High Mobility Group A1 (HMGA1) protein functions as a 'molecular switch' that activates genes required for tumor growth and invasion. Silencing HMGA1 or disrupting FGF19 signals in mouse models resulted in decreased tum...
A cell therapy using myeloid cells bound to drug delivery microparticles reduces disease burden in a preclinical multiple sclerosis model. The therapy partially reverses hind limb paralysis and improves motor functions.
Researchers have identified a new cell state in embryonic airway development, which may lead to new approaches for treating chronic respiratory diseases. The discovery highlights the crucial role of cellular heterogeneity in shaping airway biology.
Researchers developed an optimized genome-editing method that vastly reduces mutations, enabling more effective treatment of genetic diseases. The new technique uses a 'safeguard gRNA' to control DNA cleavage, reducing off-target effects and cytotoxicity.
Enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body. The drug targets B7-H3 protein overexpressed on prostate cancer cells, blocking immune system inhibition and triggering tumor cell destruction by activating immune cells.
Cancer-associated fibroblasts (CAFs) are a type of cell that plays a crucial role in the tumor microenvironment. The authors suggest that understanding CAFs is essential for developing effective cancer therapies. Research targeting CAFs has shown promise, but challenges remain due to their complex nature.
Research suggests that high doses of sucralose can lower activation of T-cells, an important component of the immune system, in mice. This finding could lead to a new way of using sucralose therapeutically to help dampen T-cell responses in patients with autoimmune diseases.
A WPI-led team used computational modeling to create a detailed picture of the SARS-COV-2 virus envelope, revealing its elliptical shape and changing structure. This discovery could lead to more effective therapies and vaccines, as well as a better understanding of the virus's properties.
Researchers at Georgia Institute of Technology developed a synthetic tumor model to understand the impact of microenvironment on targeted therapies for Activated B Cell-like Diffuse Large B cell lymphoma. The model showed promise in demonstrating how combining therapeutics can overcome tumor resistance to inhibitors.
The study found that downregulation of angulin-1/LSR leads to increased claudin-2 expression and altered cell metabolism in human lung adenocarcinoma cells, promoting malignancy. Researchers identified AG1478 and EW-7197 as potential therapeutic agents.
Researchers found significant decreases in the levels of KRAS, RHOA, RAC1, and CDC42 after PCAI treatment, implicating their role in cancer progression and metastasis. These findings support the potential of PCAIs as potent agents for developing new anticancer therapeutics.
Researchers have found that valosin-containing protein (VCP) is essential for KRAS-mutant pancreatic ductal adenocarcinoma cell growth and survival. Inhibiting VCP, combined with autophagy inhibition, enhances efficacy in preclinical studies.
Scientists have identified a new molecule that could help distinguish and treat patients with a specific subgroup of medulloblastoma, the most common malignant brain tumor in children. The discovery points to potential targeted therapies using a drug or drugs to block the molecule's activity.
Researchers found that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes, potentially boosting efficacy against solid tumors. The study suggests leaving lymph nodes intact until after immunotherapy could improve treatment outcomes for patients with head and neck cancers.
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
A team of researchers developed a novel cancer therapeutic combining antibody fragments with molecularly engineered nanoparticles, permanently eradicating gastric cancer in treated mice. The 'hit and run' drug delivery system targets HER2 proteins associated with gastric cancer.
Researchers have designed a new RNA sensor that can selectively activate synthetic genes in specific cells, opening up possibilities for targeted therapies for cancer and other diseases. The system uses an enzyme that naturally exists in most animal cells to detect and repair mismatches in double-stranded RNA.
Researchers discovered that targeting two inflammatory regulators simultaneously can boost T cell expansion and increase antitumor immune activity in models. The findings showed at least 10 times greater T cell expansion when both regulators were knocked out, resulting in improved durability.
UVA researchers discovered a metabolic pathway that can modulate COVID-19 inflammation, lung recovery, and host metabolic health. They suggest a potentially viable therapeutic agent that may be combined with existing anti-viral agents to treat severe COVID-19 in patients with underlying metabolic disease.
A new review paper suggests that selective protection of normal cells from chemotherapy could increase the therapeutic window and improve outcomes for cancer patients. The authors propose using antagonistic drug combinations to kill drug-resistant cancer cells, reducing side effects and improving quality of life.